Board of Directors

Joseph K. Piper has served as our Chairman since 2006. Mr. Piper directs the overall investment strategy for Integra Ventures. Since 1983, he has been involved with corporate governance, formation, growth, senior management, mergers and acquisitions, and investment in the healthcare industry. He currently sits on the board of several Integra Ventures portfolio companies including Blue Heron Biotechnology, HealthHelp, and Cardiometrix. Mr. Piper also serves as Chairman of the National Multiple Sclerosis Society GWC. Prior to founding Integra Ventures, Mr. Piper co-founded and served as President of Capital Services for Diversified Health Services (“DHS”) the largest post-acute care outsourcing management firm in the United States at the time, which was later sold to ServiceMaster (NYSE: SVM). Mr. Piper holds an MBA. from the University of Colorado, as well as a Juris Doctor Degree from Seattle University. He earned his B.S. in Business from Arizona State University.

Frederick J. Dechow, Ph.D. See Management Section.

Julia R. Brown has served as a director since 2001. Ms. Brown also serves on the Board of Directors of Tanox, Inc., Labopharm and Rx3 Pharmaceuticals, Inc. Ms. Brown serves on the business advisory board of CovX Pharmaceuticals and is a member of the board of the University of California, San Diego Foundation, the La Jolla Institute for Molecular Medicine, the Veterans Medical Research Foundation and CONNECT. From 2000 to 2003, Ms. Brown was Executive Vice President of Amylin Pharmaceuticals, Inc. and continues to serve as Advisor to the Chief Executive Officer. From 1995 to 1999, Ms. Brown was with Dura Pharmaceuticals, Inc., most recently serving as Executive Vice President. Ms. Brown spent over 25 years with Eli Lilly and Company in progressively more senior roles. From 1992 to 1994, Ms. Brown was Vice President of IVAC Corporation and General Manager of its Vital Signs Division, a Lilly subsidiary. Ms. Brown was Vice President of Worldwide Marketing for Hybritech, another Lilly subsidiary, and led global marketing from 1986 to 1992. Ms. Brown is a graduate of Louisiana Tech University where she studied microbiology and biochemistry.

A. Sinclair Dunlop has served as a director since 2006. Mr. Dunlop is a Director of New Business Ventures for MASA, Inc., and manages client investments in the areas of information technology, biotechnology and healthcare. A former international business and economics analyst with the Center for Strategic & International Studies in Washington, D.C., Mr. Dunlop has several years of private equity and venture capital experience in Europe, the United States and Israel. Prior to joining MASA, Mr. Dunlop was an Associate at New Vantage Group, manager of several early-stage venture capital funds. In May 2000, Mr. Dunlop received his MBA. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also holds an M.A. with honors in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Mr. Dunlop is a St. Andrews Society of New York Scholar.

Søren Schifter, M.D. DMSc, has served as a director since 2006. Dr. Schifter joined Novo A/S in 2001. Prior to this, he was Chief Physician at the Department of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, and an Associate Professor at the University of Copenhagen. He received his medical degree from the University of Aarhus, has passed the U.S. Visa Qualifying Examination (VQE) and is a specialist in Nuclear Medicine and Clinical Physiology. He is a DMSc from the University of Copenhagen and the author or co-author of a large number of refereed publications within the areas of oncology, endocrinology, regulatory peptides and nuclear medicine. He has been on the boards of scientific as well as professional organizations and has served as General Secretary of the European Specialist Section of Nuclear Medicine in addition to being a member of a number of professional committees and task groups. Dr. Schifter holds a Graduate Diploma in Economics and Business Administration from the Copenhagen Business School and has further supplemented his medical degrees with formalized management education for Chief Physicians and the Nordic Diploma Course in Health Economics. Dr. Schifter was a board member of Neurodan A/S until the company was acquired by Otto Bock HealthCare GmbH in March 2005, and is on the boards of Celltrix AB, Malmö, Sweden and Cytochroma Canada, Inc., Toronto, Canada.

Jack B. Nielsen has served a director since 2007. Mr. Nielsen joined Novo A/S as Partner in Novo Ventures in 2001. From 1990 to 2001 Mr. Nielsen held various positions in the Novo Nordisk business area which in 2000 became Novozymes A/S. Before joining Novo Ventures, he was deeply involved in designing the R&D strategy for Novozymes’ activities in the cereal food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. Mr. Nielsen has furthermore been involved in collaborations with Procter & Gamble, Danisco, and Quest International to identify new enzymes for the detergent and cereal food industry. Prior hereto, he held positions in marketing and technical services in the textile and personal care area, and started his career in the field of large-scale manufacturing of enzymes. Mr. Nielsen also serves on the board of directors of Cell Biosciences, Inc., Protein Forest, Inc., Reata Pharmaceuticals, Inc. and NeoMend, Inc., and he is a former director of Panacos Pharmaceuticals, Inc., Nuevolution A/S, and CardioOptics, Inc. Mr. Nielsen obtained his MSc in 1990 from the Technical University of Denmark, and his Master in Management of Technology from the Center for Technology, Economics and Management in Copenhagen in 2000.

Board Observers

Andy Acker, CFA, is Executive Vice President and Portfolio Manager of Janus Global Life Sciences Fund, which he has managed since May 2007. In addition, Mr. Acker is Portfolio Manager of other Janus accounts and performs duties as a research analyst. He joined Janus Capital in 1999 as a securities analyst. Mr. Acker holds a Bachelor of Science degree (magna cum laude) in Biochemical Sciences from Harvard College where he was a member of Phi Beta Kappa. He also holds a Master's degree in Business Administration with honors from Harvard Business School. Mr. Acker holds the Chartered Financial Analyst designation.

Jack Rosling is President of CITYICE Cold Storage Company, Terminal 91, Port of Seattle. CITYICE specializes in serving the seafood industry with particular emphasis on the distant-water factory trawler fleet. He was also President of Myers Metals & Minerals, which in the recent past was active on the West Coast in the international steel trade and industrial raw materials business. Additionally, he has been or is currently a director of Dant and Russell, Bainbridge Sciences, Data West Corporation, Terminal 91 Realty, Northwest Harvest and the Entrepreneurship Center Advisory Board of Albers School of Business and Economics, Seattle University. Mr. Rosling is an active member of the Puget Sound Venture Club and the Alliance of Angels. Following his military service as an officer in the U.S. Navy, he returned to Seattle in 1962 and shortly thereafter started his business career with the predecessor company of Myers Metals & Minerals. Mr. Rosling became a partner in that firm in 1968, and was appointed as its President in 1973. Mr. Rosling received a bachelor's degree in Business Administration and Economics from Whitman College.

Contact Us

• Press Releases

• Press Coverage

• Useful Links